Dermata Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Dermata Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.69M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.70M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($1.70M) | Nov 14, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($2.30M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.30M) | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($2.30M) | Aug 13, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.17M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.83M) | Aug 13, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($2.83M) | Nov 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($3.13M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.13M) | May 14, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($3.13M) | Aug 13, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($1.72M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($1.70M) | Aug 7, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($1.70M) | Nov 13, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($2.24M) | Aug 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($2.24M) | May 15, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($2.24M) | Nov 13, 2024 |
| Q1 | 2023 | Dec 31, 2022 | ($2.79M) | May 11, 2023 |
| Q3 | 2023 | Sep 30, 2022 | ($2.42M) | Nov 9, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($1.76M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($1.77M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.34M) | May 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.23M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.88M) | Aug 13, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.20M) | May 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($1.81M) | Nov 13, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($1.73M) | Aug 7, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($2.28M) | May 15, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($2.45M) | Nov 9, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($2.73M) | Aug 10, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($2.79M) | May 11, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($1.71M) | Nov 10, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($1.33M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($2.26M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($540.1K) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($792.8K) | Sep 27, 2021 |